Glucovance® in type 2 diabetes, a fixed metformin-glibenclamide combined therapy for a bipolar metabolic disease;Le médicament du mois. Glucovance® dans le diabète de type 2, une association fixe metformine-glibenclamide pour faciliter le traitement d'une maladie bipolaire

Revue Medicale de Liege

Volumn 58, Issue 6, 2003, Pages 448-452

  Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Glibenclamide; Insulin secretion; Insulin sensitivity; Metformin; Sulphonylurea; Type 2 diabetes

Indexed keywords

BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; BELGIUM; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; VOMITING;

BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; PATIENT COMPLIANCE; PERIODICITY;

EID: 0042155384     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Scheen AJ, Paquot N, Lefèbvre PJ. - Etiologie et physiopathologie du diabète de type 2. Encyclopédie Médico-Chirurgicale (Paris-France). Endocrinologie-Nutrition, 1995, 10-366-D-10, 7p.
2. Scheen AJ. - L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège, 1999, 54, 87-94.
3. Scheen AJ, Lefèbvre PJ. - Le diabète non insulinodépendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg, 1996, 151, 395-405.
4. Scheen AJ, Lefèbvre PJ. - Insulin resistance vs. insulin deficiency: which comes first? The old question revisited. In Diabetes in the New Millennium. Eds Di Mario U., Leonetti F., Pugliese G., Sbraccia P. and Signore A., J. Wiley & Sons, New York, 2000, 101-113.
5. Turner RC, Cull CA, Frighi V, Holman RR. - Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999, 281, 2005-2012.
6. Scheen AJ, Paquot N. - Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
7. Scheen AJ, Estrella F. - L'étude Steno-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.
8. Scheen AJ. - Current management of coexisting obesity and type 2 diabetes. Drugs, 2003, 63, 1165-1184.
9. Scheen AJ, Lefèbvre PJ. - Oral antidiabetic agents. A guide to selection. Drugs, 1998, 55, 225-236.
10. European Diabetes Policy Group. - A desktop guide to Type 2 diabetes mellitus. Diabet Med, 1999, 16, 716-730.
11. Scheen AJ, Lefèbvre PJ. - Treatment of diabetes mellitus. In: Clinical Pharmacology, (Ed: C. Sirtori), Mc Graw Hill, London, 2000, 685-698.
12. Luyckx A, Daubresse JC, Carpentier JL, Lefèbvre P. - La place des biguanides dans le traitement du diabète sucré. In: Journées Annuelles de Diabétologie de l'Hôtel-Dieu, Flammarion Médecine-Sciences, Paris, 1974, 35-52.
13. Cusi K, DeFronzo RA. - Metformin: a review of its metabolic effects. Diabetes Rev, 1998, 6, 89-131.
14. DeFronzo RA. - Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999, 131, 281-303.
15. Howlett H, Porte F, Allavoine T, et al. - The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin, 2003, 19, 218-225.
16. Scheen AJ. - La non-observance thérapeutique: problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 1999, 54, 914-920.
17. Paes AHP, Bakker A, Soe-Agbie CJ. - Impact of dose frequency on patient compliance. Diabetes Care, 1997, 20, 1512-1517.
18. Marathe PH, Arnold ME, Meeker J, et al. - Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol, 2000, 40, 1494-1502.
19. Scheen AJ, Letiexhe MR, Lefèbvre PJ. - Short administration of metformin improves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabetic Med, 1995, 12, 985-989.
20. Scheen AJ. - Clinical pharmacokinetics of metformin. Clin Pharmacokin, 1996, 30, 359-371.
21. Scheen AJ. - Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
22. Scheen AJ. - Les sulfamidés hypoglycémiants, 50 ans après Loubatières. Rev Med Liège, 1996, 51, 90-93.
23. Scheen A, Jaminet C, Luyckx A, Lefèbvre P. - Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420 in non insulin-dependent (type 2) diabetes. Int J Clin Pharmacol, 1987, 25, 70-76.
24. Scheen A, Luyckx A, Castillo M, Lefèbvre P. - Rôle thérapeutique des effets extra-pancréatiques des sulfamidés hypoglycémiants. Med Hyg, 1985, 43, 3816-3820.
25. Hermann LS, Schersten B, Melander A. - Antihyperglycaemic efficacy, response prediction and dose-relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med, 1994, 11, 953-960.
26. Marre M, Howlett H, Lehert P, Allavoine T. - Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled with metformin. Diabetic Med, 2002, 19, 673-680.
27. Blonde L, Rosenstock J, Mooradian AD, et al. - Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diab Obes Metab, 2002, 4, 368-375.
28. Garber AJ, Bruce S, Fiedorek FT. - Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther, 2002, 24, 1401-1413.
29. Garber A, Marre M, Blonde L, et al. - Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. Diab Obes Metab, 2003, 5, 171-179.
30. Garber AJ, Larsen J, Schneider SH, et al. - Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diab Obes Metab, 2002, 4, 201-208.
31. Dailey G, Kim MS, Lian JF. - Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic paients. J Int Med Res, 2002, 30, 71-79.
32. Melikian C, White TJ, Vanderplas A, et al. - Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther, 2002, 24, 460-467.
33. Scheen AJ, Bruwier G, Schmitt H, au nom des membres de l'étude clinique DREAM. - Optimalisation de la prise en charge du patient diabétique de type 2: résultats de l'étude "DREAM" en médecine générale. Rev Med Liège, 2003, 58, 139-146.